WeVote
Log In

Bill

Bill

A 9360

Relates to requiring Medicaid coverage of FDA-approved GLP-1 receptor agonist medications for certain purposes

2025 Regular Session Introduced by Angelo Santabarbara

New York would mandate Medicaid coverage of GLP-1 drugs for specified conditions, expanding access while increasing state healthcare costs and removing prescribing safeguards.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 9360

Legislative bill overview

Bill A 9360 would require New York's Medicaid program to cover FDA-approved GLP-1 receptor agonist medications (drugs like semaglutide/Ozempic and tirzepatide/Zepbound) for certain specified purposes. The bill mandates coverage regardless of prior authorization requirements or step therapy protocols that might otherwise delay or prevent access to these medications.

Why is this important

GLP-1 receptor agonists have become increasingly sought-after medications, with significant demand exceeding supply in some cases. Medicaid covers roughly 4.3 million New Yorkers, so this mandate would substantially expand access to these drugs for low-income residents while also creating a significant budget obligation for the state's Medicaid program, which already faces substantial fiscal pressures.

Potential points of contention

  • Cost implications: GLP-1 medications are expensive (several thousand dollars annually); mandatory coverage without cost controls could substantially increase state Medicaid spending and potentially require reallocation from other healthcare services
  • Scope ambiguity: The bill references "certain purposes" but the specific medical indications are not detailed in available summaries—clarification needed on whether this covers weight loss, diabetes, cardiovascular disease, or all approved uses
  • Prior authorization concerns: While removing barriers may improve access, eliminating clinical review mechanisms could lead to inappropriate prescribing or use in patients who might benefit from alternative treatments

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.